January 18, 2010 — Richmond, Virginia — Health Diagnostic Laboratory, Inc. (HDL), www.hdlabinc.com, announced today the launch of its new preventative model to chronic disease management based off a monumental shift in the way physicians test for life threatening conditions. “Few moments in medical history have held such promise and opportunity for the prevention of cardiovascular and related chronic diseases while enhancing the continuum of care,” said Tonya Mallory, President and CEO, HDL, Inc. “The medical community is no longer confined to limited lab results, and is in a position to now more accurately detect the unexpected.”
Health Diagnostic Laboratory, Inc., headquartered in a new state-of-the-art facility in the Virginia BioTechnology Research Park, offers a comprehensive panel of tests to help physicians personalize treatment based on an expanded, total patient profile. As a result, HDL, Inc. provides earlier detection of residual risk factors pre-disposing patients to disease, more advanced evidence-based treatments, and fewer patients progressing to overt disease.
50% of people with coronary artery disease have had blood cholesterol levels similar to those of people who do not develop the disease. As a result, there has been a marked change the overall scientific understanding of the role of “good” and “bad” cholesterol in metabolic disorders and coronary heart disease (CHD) events. “We can’t afford surprises, or limited data any longer,” said Mallory. “After 50 plus years of research it is now proven that physicians must measure more in order to understand a patient’s overall risks.”
HDL, Inc.’s new preventative model approach provides physicians with more advanced tools and scientific evidence to predict angiographic disease or coronary heart disease events. Positioned as a partner to both the physician and the patient, HDL, Inc. moves beyond total cholesterol and outdated measurement techniques, and instead provides physicians with comprehensive and accurate information that surpasses the reach of conventional HDL and LDL analysis. Physicians therefore can do more than diagnose disease; they can focus on all of the cholesterol components and residual risk factors or biomarkers, and their impact on overall heath.
The founders of HDL, Inc., a fully CAP/CLIA accredited clinical laboratory, have a rich history of serving at the forefront of renowned medical, educational, and industrial institutions. HDL, Inc. uses a comprehensive systems biology approach to eliminate surprises and reverse the alarming increase in chronic disease by providing physicians with:
* access to targeted disease management services for their patients
* improved compliance with treatment plans
* clinical educators to increase patient satisfaction
“HDL, Inc. diligently works as a partner with both physician and patient to understand disease, and provide support to identify and reverse health risks,” said Mallory. HDL, Inc.’s advanced testing options allows physicians to understand their patients’ disease on a personal level, and to support the individual achievement of health in a way that was never before possible.
Health Diagnostic Laboratory, Inc. (HDL, Inc.) is an accredited clinical laboratory focused on disease state management with supporting clinical laboratory testing targeting patients with cardiovascular disease (CVD), heart failure, stroke, diabetes mellitus (DM), metabolic syndrome (MS), and nonalcoholic steatohepatitis or fatty liver disease (NASH). HDL, Inc. offers a unique menu of clinical laboratory test results, selected based on their ability to discern the information required to understand each patient’s disease state.
Health Diagnostic Laboratory, Inc. | 737 N. 5th Street, Suite 103 | Richmond, VA 23219
1.877.4HDLABS (1.877.443.5227) | www.hdlabinc.com